Léčebná studie Relapsed AML 2001/01, 02 pro děti s relapsem akutní myeloidní leukemie nebo primárně rezistentní nemocí zlepšila jejich nadeji na vyléčení.

Warning

This publication doesn't include Faculty of Medicine. It includes Central European Institute of Technology. Official publication website can be found on muni.cz.
Title in English The Relapsed AML 2001/01, 02 study for children with relapsed acute myeloid leukaemia or initially resistant disease has improved outcome
Authors

ZDRÁHALOVÁ K. SEDLÁČEK P. SMÍŠEK P. KESLOVÁ P. ŠTĚRBA Jaroslav HRSTKOVÁ Hana BLAŽEK B. MIHÁL V. HAK J. PROCHÁZKOVÁ D. ČERNÁ Z. TIMR P. ZEMANOVÁ Z. JAROŠOVÁ M. OLTOVÁ Alexandra SCHWARZ J. POSPÍŠILOVÁ Šárka MEJSTŘÍKOVÁ Ester HRUŠÁK O. ZUNA J. VODIČKOVÁ E. ZÁMKOVÁ A. BLATNÝ J. ZAPLETAL O. VÁVRA V. JANOTOVÁ I. STARÝ J.

Year of publication 2011
Type Article in Periodical
Magazine / Source Transfuze a hematologie dnes
MU Faculty or unit

Central European Institute of Technology

Citation
Field Oncology and hematology
Keywords acute myeloid leukemia; relapse; resistance; Relapsed AML 2001; children
Description Relapse of acute myeloid leukaemia (AML) or AML initially resistant to treatment is extremely prognostically unfavourable. Between VIII/2001 and III/2009 in the Czech Republic, twenty patients aged 0-18 years with diagnosis were treated as part of the international Relapsed AML 2001/01 study.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info